Authors: Nuijen, B Bouma, M Talsma, H Manada, C Jimeno, JM Lopez-Lazaro, L Bult, A Beijnen, JH

Citation: B. Nuijen et al., Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F, DRUG DEV IN, 27(8), 2001, pp. 767-780

Authors: Nuijen, B Bouma, M Manada, C Jimeno, JM Lazaro, LL Bult, A Beijnen, JH

Citation: B. Nuijen et al., Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices, INV NEW DR, 19(4), 2001, pp. 273-281

Authors: Nuijen, B Bouma, M Schellens, JHM Beijnen, JH

Citation: B. Nuijen et al., Progress in the development of alternative pharmaceutical formulations of taxanes, INV NEW DR, 19(2), 2001, pp. 143-153

Authors: Nuijen, B Bouma, M Manada, C Jimeno, JM Schellens, JHM Bult, A Beijnen, JH

Citation: B. Nuijen et al., Pharmaceutical development of anticancer agents derived from marine sources, ANTI-CANC D, 11(10), 2000, pp. 793-811

Authors: Nuijen, B Bouma, M Henrar, REC Brauns, U Bette, P Bult, A Beijnen, JH

Citation: B. Nuijen et al., In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS, INT J PHARM, 194(2), 2000, pp. 261-267

Authors: Nuijen, B Bouma, M Henrar, REC Manada, C Bult, A Beijnen, JH

Citation: B. Nuijen et al., Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration, ANTI-CANC D, 10(10), 1999, pp. 879-887